Anthony C. Tridico, Ph.D.

Anthony has over 20 years of experience representing clients with a focus on patent office trials and appeals (PTAB and EPO), patent prosecution management, IP due diligence and litigation. His practice includes experience in a variety of technical areas including biologics, immunology and biotechnology, chemical and pharmaceutical sciences, polymers and adhesives, food sciences, medical devices, and diagnostics and instrumentation.

A significant portion of Anthony’s current practice is devoted to post-grant proceedings, appeals and oral hearings at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), as well as European Patent Office (EPO) opposition and appeal procedures. Anthony, serving as lead counsel, has argued and won on behalf of both patent owners and petitioners in inter partes and ex partes proceedings before the PTAB. He has successfully represented numerous clients in inter partes reexaminations and ex parte reexaminations post-grant proceedings invaliding competitor patents and helping to clear the way for freedom to operate.

Anthony also focuses on international patent prosecution and portfolio management as well as strategic counseling including pre-litigation strategy, due diligence investigations, freedom to operate analysis and the specialized areas of patent term extensions and Orange Book listings. He works closely with clients to develop IP strategies with an eye towards litigation. He has also successfully represented clients in U.S. district court and multi-national patent litigations including protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations.

Anthony is a well-known authority on various intellectual property issues and is a frequent speaker at international programs and conferences and he has spoken before numerous Fortune 500 companies and multi-national organizations throughout the world. He served for over 10 years as adjunct professor at Georgetown University Law School teaching patent law and patent prosecution, and he is a lecturer on U.S. patent law at Queen Mary University of London.

Over the years, Anthony has been recognized by Intellectual Asset Management (IAM) as a leading patent prosecutor in the United Kingdom and Europe in the IAM Patent 1000, and as a Global Leader as well as a top IP strategist by the IAM Strategy 300. Managing Intellectual Property named him an “IP Star” in the United Kingdom.

Anthony is currently lead counsel for several clients in the chemical and biotech industries in inter partes review (IPR) post-grant review (PGR) proceedings challenging the validity of competitor patents. He is also defending a client in an inter partes reexamination and appeal before the PTAB regarding its patent portfolio directed to G-CSF analogs. For another client, he is coordinating European opposition proceedings while providing strategic counseling of the U.S. patent portfolio for a European biotech company regarding a FDA-approved product. He provides strategic counseling, patent prosecution, and portfolio management of the global IP portfolio for Capsugel following the $2 billion spin off of the company from Pfizer.